Suchergebnisse - "Breccia, Massimo"

PubPharm (960)

1

Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation

enthalten in: European journal of haematology | 2024

von Laganà, A. | Passucci, M. | Pepe, S. | +7

2

First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis

enthalten in: Blood | 2024

von Crespiatico, I. | Zaghi, M. | Mastini, C. | +37

CommentIn: Blood. 2024 Apr 4;143(14):1323-1324. - PMID 38573606

3

Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?

enthalten in: Leukemia | 2024

von Kantarjian, H. | Branford, S. | Breccia, M. | +9

4

Early death risk score in acute promyelocytic leukemia : A retrospective analysis from a monocentric cohort

enthalten in: European journal of haematology | 2024

von Costa, A. | Carmosino, I. | Scalzulli, E. | +10

5

Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy

enthalten in: Cancer | 2024

von Palandri, F. | Palumbo, G. | Benevolo, G. | +34

6

ROP-ET : a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options

enthalten in: Annals of hematology | 2024

von Kiladjian, J. | Marin, F. | Al-Ali, H. | +38

7

Pharmacotherapeutic advances for chronic myelogenous leukemia : beyond tyrosine kinase inhibitors

enthalten in: Expert opinion on pharmacotherapy | 2024

von Costa, A. | Scalzulli, E. | Carmosino, I. | +4

8

How to improve treatment-free remission eligibility in chronic myeloid leukaemia?

enthalten in: British journal of haematology | 2024

von Costa, A. | Breccia, M.

9

e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response

enthalten in: Journal of clinical medicine | 2024

von Marcé, S. | Méndez, A. | Xicoy, B. | +19

10

The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib

enthalten in: Annals of hematology | 2024

von Mulas, O. | Abruzzese, E. | Luciano, L. | +26

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[96]